Tracon Pharmaceuticals said today it has licensed two preclinical oncology candidates from Johnson & Johnson’s Janssen Pharmaceutica, which will retain rights to potentially reacquire the programs.
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform ...
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform ...
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
TRACON Pharmaceuticals (NASDAQ: TCON) has announced interim results from their Phase II ENVASARC pivotal trial of envafolimab, expressing confidence in the drug's potential during their Q4 and ...
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform ...
Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call. [Operator Instructions]. During today's call, we will be making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results